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Premedication With Meloxicam Exacerbates Intracranial Hemorrhage in
an Immature Swine Model of Non-impact Inertial Head Injury
Abstract
Meloxicam is a cyclo-oxgenase-2 preferential non-steroid anti-inflammatory drug with very effective analgesic
and anti-inflammatory effects in swine. Previous reports in piglets have demonstrated that meloxicam also
inhibits cyclo-oxgenase-1 and reduces production of thromboxane significantly. We use pre-injury analgesia in
our immature swine (3–5 day old piglets) model of brain injury using rapid head rotations without impact. In
23 consecutive subjects we found that premedication with meloxicam (N=6) produced a significantly higher
mortality rate (5/6 or 83%) than buprenorphine (N =17, 1/17 or 6%, p < 0.02). On gross neuropathologic
examination of the meloxicam-treated swine, we observed massive subdural and subarachnoid bleeding which
were not present in buprenorphine-premedicated animals. To our knowledge there are no previous reports in
swine of increased bleeding or platelet inhibition associated with meloxicam administration and further
research is needed to define mechanisms of action in piglets. We caution the use of meloxicam in swine when
inhibition of platelet aggregation might adversely affect refinement of experimental research protocols, such as
in stroke, trauma, and cardiac arrest models.
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Premedication with meloxicam exacerbates intracranial
hemorrhage in an immature swine model of non-impact inertial
head injury
SH Friessa, MY Naima, TJ Kilbaugha, J Ralstonb, and SS Marguliesb
aDepartment of Anesthesiology and Critical Care Medicine, The Children’s Hospital of
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Abstract
Meloxicam is a cyclo-oxgenase-2 preferential non-steroid anti-inflammatory drug with very
effective analgesic and anti-inflammatory effects in swine. Previous reports in piglets have
demonstrated that meloxicam also inhibits cyclo-oxgenase-1 and reduces production of
thromboxane significantly. We use pre-injury analgesia in our immature swine (3–5 day old
piglets) model of brain injury using rapid head rotations without impact. In 23 consecutive
subjects we found that premedication with meloxicam (N=6) produced a significantly higher
mortality rate (5/6 or 83%) than buprenorphine (N =17, 1/17 or 6%, p < 0.02). On gross
neuropathologic examination of the meloxicam-treated swine, we observed massive subdural and
subarachnoid bleeding which were not present in buprenorphine-premedicated animals. To our
knowledge there are no previous reports in swine of increased bleeding or platelet inhibition
associated with meloxicam administration and further research is needed to define mechanisms of
action in piglets. We caution the use of meloxicam in swine when inhibition of platelet
aggregation might adversely affect refinement of experimental research protocols, such as in
stroke, trauma, and cardiac arrest models.
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Swine have become a popular laboratory animal model for biomedical research. Swine have
several advantages over small animal models for modeling human disease, including
physiology and organ structure and maturation. Moreover, large animals offer the
opportunity to use instrumentation designed for humans. Adequate anesthesia and analgesia
during and after procedures which may produce pain or discomfort must be provided.
Analgesic drugs have various pharmacodynamic effects which may vary by species and age,
and can affect study outcome measures.
Two common classes of medications to provide analgesia to swine are opioids and non-
steroidal anti-inflammatory drugs (NSAIDs). Opioid analgesics can cause central nervous
system depression and decreased respiratory drive, which may be undesirable side effects in
physiologic studies. NSAIDs have the advantage of providing analgesia without these
unwanted physiologic side effects. NSAIDs provide analgesia by inhibiting the activity of
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cyclo-oxygenase (COX). COX is an enzyme that catalyzes the conversion of arachidonic
acid into prostaglandin-like molecules. There are two important isoforms: COX-1 and
COX-2. COX-1 inhibition by non-preferential NSAIDs disrupts normal gastrointestinal and
platelet physiology. COX-1 within platelets is responsible for the production of
prostaglandin H2 which in turn is converted into thromboxane A2 (TxA2). TxA2 plays a
major role in platelet aggregation and clotting. To avoid the COX-1 dependent adverse
effects, COX-2 preferential inhibitors have been developed. Meloxicam (Metacam,
Boehringer Ingelheim Vetmedica, Inc) is a COX-2 preferential NSAID which is marketed
for use in humans as well as several domestic species including swine. Previous studies of
meloxicam administration in swine have reported COX-1 inhibition, but adverse bleeding
side effects have not been observed.(1–3) We hypothesize that meloxicam in swine may
result in increased intracranial bleeding and mortality rates in our model of traumatic brain
injury and adversely affect refinement of experimental research protocols. We have
developed an immature swine model of non-impact inertial head injury which produces
detectable neurobehavioral deficits and in this communication we report our experience
using two different analgesia plans; a opioid based (buprenorphine) compared to an COX-2
preferential NSAID (meloxicam). (4) Of note, all protocols were approved by the Institute of
Animal Care and Use Committee of the University of Pennsylvania. Under general
anesthesia (isoflurane 2–4%), 3–5 day old farm piglets’ heads (N =23) were secured to a
padded bite plate. Then using the HYGE pneumatic actuator, piglets experienced head
rotation rotations in the axial direction (160–200 rad/s)(5, 6). Rotational velocity was
measured by an angular rate sensor (ATA, Inc.) attached to the linkage of the sidearm. After
the head rotation, animals were monitored for return of pinch reflex and extubated and
survived for several days for neurobehavioral outcome studies. Return of pinch reflex
usually occured on average 6–7 minutes after the head rotation, and animals were able to
appropriately ambulate, vocalize and feed within 2 hours of injury before being returned to
general husbandry care.(4, 7) Neurobehvarioal deficits in visual based problem solving and
open field behavior are observed in injured animals compared to sham animals on post
injury day 1 and 4 but resolve by post injury day 11.(4) On neuropathologic examination, we
typically observe diffuse axonal injury (β-amyloid precursor protein
immunohistochemistry), as well as scattered amounts of subarachnoid and subdural
hemorrhage.
Historically, we had previously premedicated animals with burprenorphine 0.02mg/kg
intramusculary (IM) prior to injury with a low mortality rate (5–10%), but with the concerns
of possible central nervous depression and alteration in physiology and respiratory drive, a
switch was made to the NSAID, meloxicam. Six animals were premedicated with
meloxicam 0.2 mg/kg IM, and we observed a mortality rate of 83% within 24 hours
following head rotation (Table 1). Meloxicam premedication was then discontinued in favor
of buprenorphine for the next 17 consecutive subjects with a return to our expected mortality
rate (1/17, 6%), despite no reduction in angular velocity of the head (Table 1). Gross
neuropathologic evaluation of the meloxicam-treated animals revealed massive subdural and
subarachnoid bleeding with mass effect, whereas buprenorphine-treated animals had thin
subdual and subarachnoid hemorrhage accumulations in the sulci. Due to the high early
mortality rate of the meloxicam treated group, we were unable to perfusion fix the brains
and compare axonal injury assessed by immunohistochemistry between the 2 groups.
Meloxicam is marketed as a preferential COX-2 inhibitor. Human studies have
demonstrated that meloxicam does inhibit TxA2 formation but not to significant levels that
alter in vivo platelet function or clotting times.(8) However, NSAID selectivity of COX
isoform inhibition can be species dependent.(9) Fosse et al performed pharmacokinetic and
pharmacodynamic studies of meloxicam in 2–3 week old farm piglets.(3) A carrageenan-
sponge model of acute inflammation was used to evaluate the effects of meloxicam.
Animals received meloxicam 0.4 mg/kg intravenously or saline vehicle. Exudate levels of
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prostaglandin E2 were measured as an indirect indicator of COX-2 activity and serum levels
of thromboxane B2 (TxB2) as an indicator of COX-1 activity. Profound inhibition of TxB2
was observed for at least 8 hours after administration of meloxicam, indicating strong
inhibition of COX-1 in piglets.(3) In another study, 2 month old swine were challenged with
endotoxin and randomized to treatment with meloxicam or placebo. TxB2 levels were found
to be markedly reduced in meloxicam treated animals compared to placebo.(10)
Unfortunately, no coagulation profile or platelet aggregation studies were performed in
either study to determine if decreased TxB2 levels resulted in alterations in bleeding times or
platelet aggregation. Our swine model may be more sensitive to smaller changes in platelet
aggregation associated with COX-1 inhibtion, due to the known clinical association of
traumatic brain injury with coagulopathy.(11)
Our experience with meloxicam in our head injury model would corroborate the strong
COX-1 inhibition by meloxicam in immature swine previously reported. (3, 10) Unlike the
buprenorphine-premedicated animals,most of the meloxicam-treated piglets developed lethal
massive intracranial hemorrhage after experiencing non-impact head rotation. We speculate
that the unexpected lethal intracranial hemorrhage was the result of meloxicam inhibition of
COX-1, resulting in decreased TxA2 levels, and reduction in platelet aggregation. Although
meloxicam appears to have higher selectivity for COX-2 inhibition, its COX-1 selectivity is
not trivial(3). We caution the use of meloxicam in swine when inhibition of platelet
aggregation might adversely affect refinement of experimental research protocols, such as in
stroke, trauma, and cardiac arrest models. Further research is needed to define meloxicam’s
effects in swine on bleeding and platelet aggregation.
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Table 1
Mortality and angular velocity of meloxicam and buprenorphine-treated piglets
Meloxicam Buprenorphine
Mortality (%) 5/6 (83%) 1/17 (6%)*
Angular Velocity (rad/s) 187.2 ± 6.7 194.3 ± 6.9^
*
p < 0.02 by Chi-square test,
^
p = 0.06 by student t-test
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